Experimental models of abdominal aortic aneurysms

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 2, 2010, Pages 221-230

  Tsui, Janice C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Abdominal aortic aneurysms (AAA); Elastase infusion; Experimental models

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CALCIUM CHLORIDE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; ENALOPRIL; GELATINASE B; INDOMETACIN; INTERLEUKIN 6; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN; UNCLASSIFIED DRUG; VALSARTAN;

ABDOMINAL AORTA ANEURYSM; CHEMICAL MODEL; DISEASE ACTIVITY; DISEASE COURSE; DRUG MECHANISM; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; GENETIC PREDISPOSITION; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PHYSICAL MODEL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TREATMENT DURATION;

EID: 84855500740     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010221     Document Type: Review

References (102)

1. Thompson MM, Bell PR. ABC of arterial and venous disease. Arterial aneurysms. Br Med J 2000; 320: 1193-6.
2. Crane J, Cheshire N. Recent developments in vascular surgery. BMJ 2003; 327: 911-5.
3. Lindblad B, Borner G, Gottsater A. Factors associated with developmentof large abdominal aortic aneurysm in middle-aged men. Eur J Vasc Endovasc Surg 2005; 30: 346-52.
4. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors forabdominal aortic aneurysms: a 7-year prospective study: theTromso Study, 1994-2001. Circulation 2009; 119: 2202-8.
5. Mortality results for randomised controlled trial of early electivesurgery or ultrasonographic surveillance for small abdominal aorticaneurysms. The UK Small Aneurysm Trial Participants. Lancet1998; 352: 1649-55.
6. EVAR trial participants. Endovascular aneurysm repair versus openrepair in patients with abdominal aortic aneurysm (EVAR trial 1):randomised controlled trial. Lancet 2005; 365: 2179-86.
7. Guessous I, Periard D, Lorenzetti D, Cornuz J, Ghali WA. Theefficacy of pharmacotherapy for decreasing the expansion rate ofabdominal aortic aneurysms: a systematic review and metaanalysis. PLoS One 2008; 3: e1895.
8. Guo DC, Papke CL, He R, Milewicz DM. Pathogenesis of thoracicand abdominal aortic aneurysms. Ann N Y Acad Sci 2006; 1085:339-52.
9. Thompson MM, Wills A, McDermott E, Crowther M, Brindle N, Bell PR. An in vitro model of aneurysmal disease: effect ofleukocyte infiltration and shear stress on MMP production withinthe arterial wall. Ann N Y Acad Sci 1996; 800: 270-3.
10. Wills A, Thompson MM, Crowther M, et al. Elastase-inducedmatrix degradation in arterial organ cultures: an in vitro model ofaneurysmal disease. J Vasc Surg 1996; 24: 667-79.
11. Schurink GW, Aarts NJ, Wilde J, et al. Endoleakage after stentgrafttreatment of abdominal aneurysm: implications on pressureand imaging--an in vitro study. J Vasc Surg 1998; 28: 234-41.
12. Dias NV, Ivancev K, Malina M, et al. Direct intra-aneurysm sacpressure measurement using tip-pressure sensors: in vivo and in vitroevaluation. J Vasc Surg 2004; 40: 711-6.
13. Springer F, Schlierf R, Pfeffer JG, Mahnken AH, Schnakenberg U, Schmitz-Rode T. Detecting endoleaks after endovascular AAA repairwith a minimally invasive, implantable, telemetric pressuresensor: an in vitro study. Eur Radiol 2007; 17: 2589-97.
14. Gresham GA, Howard AN. Aortic rupture in the turkey. J AtherosclerRes 1961; 1: 75-80.
15. Simpson CF, Kling JM, Palma RF. Beta-aminopropriomitrileinduceddissecting aneurysms of turkeys: treatment with propanalol. Toxicol Appl Pharmacol 1970; 16: 143-53.
16. Simpson CF. Relation of hemodynamics to the incidence of diethylstilbestrol-induced aortic ruptures in hypertensive and hypotensivelines of turkeys. Atherosclerosis 1978; 30: 249-54.
17. Simpson CF, Kling JM, Robbins RC, Harms RH. Betaaminoproprionitrile-induced aortic ruptures in turkey and inhibitionby reserpine and enhancement by monoamine oxidase inhibitors. Toxicol Appl Pharmacol 1968; 12: 48-59.
18. Simpson CF, Boucek RJ. The B-aminopropionitrile-fed turkey: amodel for detecting potential drug action on arterial tissue. CardiovascRes 1983; 17: 26-32.
19. Simpson CF, Kling JM, Palmer RF. The use of propranololfor the protection of turkeys from the development of betaaminopropionitrile-induced aortic ruptures. Angiology 1968; 19:414-8.
20. Andrews EJ, White WJ, Bullock LP. Spontaneous aortic aneurysmsin blotchy mice. Am J Pathol 1975; 78: 199-210.
21. Hunt DM. Primary defect in copper transport underlies mottledmutants in the mouse. Nature 1974; 249(460): 852-4.
22. Brophy C, Tilson JE, Tilson MD. Propranolol delays the formationof aneurysms in the male blotchy mouse. J Surg Res 1988; 44: 687-9.
23. Brophy CM, Tilson JE, Tilson MD. Propranolol stimulates thecrosslinking of matrix components in skin from the aneurysmproneblotchy mouse. J Surg Res 1989; 46: 330-2.
24. Reilly JM, Savage EB, Brophy CM, Tilson MD. Hydrocortisonerapidly induces aortic rupture in a genetically susceptible mouse. Arch Surg 1990; 125: 707-9.
25. Senapati A, Carlsson LK, Fletcher CD, Browse NL, Thompson RP. Is tissue copper deficiency associated with aortic aneurysms? Br JSurg 1985; 72: 352-3.
26. Jaakkola P, Hippelainen M, Kantola M. Copper and zinc concentrationsof abdominal aorta and liver in patients with infrarenal abdominalaortic aneurysm or aortoiliacal occlusive disease. AnnChir Gynaecol 1994; 83: 304-8.
27. Maki JM, Rasanen J, Tikkanen H, et al. Inactivation of the lysyloxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 2002; 106: 2503-9.
28. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosisin murine models: correlation between lesions in the aorticorigin and in the entire aorta, and differences in the extent of lesionsbetween sexes in LDL receptor-deficient and apolipoproteinE-deficient mice. J Lipid Res 1995; 36: 2320-8.
29. Fukamizu A, Sugimura K, Takimoto E, et al. Chimeric reninangiotensinsystem demonstrates sustained increase in blood pressureof transgenic mice carrying both human renin and human angiotensinogengenes. J Biol Chem 1993; 268: 11617-21.
30. Nishijo N, Sugiyama F, Kimoto K, et al. Salt-sensitive aortic aneurysmand rupture in hypertensive transgenic mice that overproduceangiotensin II. Lab Invest 1998; 78: 1059-66.
31. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atheroscleroticplaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol2001; 21: 1440-5.
32. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque butenhanced aneurysm formation in mice with inactivation of the tissueinhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res 2002;90: 897-903.
33. Gertz SD, Kurgan A, Eisenberg D. Aneurysm of the rabbit commoncarotid artery induced by periarterial application of calciumchloride in vivo. J Clin Invest 1988; 81: 649-56.
34. Freestone T, Turner RJ, Higman DJ, Lever MJ, Powell JT. Influenceof hypercholesterolemia and adventitial inflammation on thedevelopment of aortic aneurysm in rabbits. Arterioscler ThrombVasc Biol 1997; 17: 10-7.
35. Chiou AC, Chiu B, Pearce WH. Murine aortic aneurysm producedby periarterial application of calcium chloride. J Surg Res 2001;99: 371-6.
36. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produceaortic aneurysms. J Clin Invest 2002; 110: 625-32.
37. Longo GM, Buda SJ, Fiotta N, et al. MMP-12 has a role inabdominal aortic aneurysms in mice. Surgery 2005; 137: 457-62.
38. Xiong W, Knispel R, Mactaggart J, Baxter BT. Effects of tissueinhibitor of metalloproteinase 2 deficiency on aneurysm formation. J Vasc Surg 2006; 44: 1061-66.
39. MacTaggart JN, Xiong W, Knispel R, Baxter BT. Deletion ofCCR2 but not CCR5 or CXCR3 inhibits aortic aneurysm formation. Surgery 2007; 142: 284-8.
40. Karapolat S, Unlu Y, Erkut B, Kocak H, Erdogan F. Influence ofindomethacin in the rat aneurysm model. Ann Vasc Surg 2006; 20:369-75.
41. Isenburg JC, Simionescu DT, Starcher BC, Vyavahare NR. Elastinstabilization for treatment of abdominal aortic aneurysms. Circulation2007; 115: 1729-37.
42. Anidjar S, Osborne-Pellegrin M, Coutard M, Michel JB. Arterialhypertension and aneurysmal dilatation. Kidney Int Suppl 1992;37: S61-6.
43. Gadowski GR, Ricci MA, Hendley ED, Pilcher DB. Hypertensionaccelerates the growth of experimental aortic aneurysms. J SurgRes 1993; 54: 431-6.
44. Cho BS, Woodrum DT, Roelofs KJ, Stanley JC, Henke PK, UpchurchGR, Jr. Differential regulation of aortic growth in male andfemale rodents is associated with AAA development. J Surg Res2009; 155: 330-8.
45. Lederle FA, Nelson DB, Joseph AM. Smokers' relative risk foraortic aneurysm compared with other smoking-related diseases: asystematic review. J Vasc Surg 2003; 38: 329-34.
46. Bergoeing MP, Arif B, Hackmann AE, Ennis TL, Thompson RW, Curci JA. Cigarette smoking increases aortic dilatation withoutaffecting matrix metalloproteinase-9 and-12 expression in amodified mouse model of aneurysm formation. J Vasc Surg 2007;45: 1217-27.
47. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption ofmatrix metalloproteinase-9 (gelatinase B) suppresses developmentof experimental abdominal aortic aneurysms. J Clin Invest 2000;105: 1641-9.
48. Eskandari MK, Vijungco JD, Flores A, Borensztajn J, Shively V, Pearce WH. Enhanced abdominal aortic aneurysm in TIMP-1-deficient mice. J Surg Res 2005; 123: 289-93.
49. Lee JK, Borhani M, Ennis TL, Upchurch GR, Jr., ThompsonRW. Experimental abdominal aortic aneurysms in mice lackingexpression of inducible nitric oxide synthase. Arterioscler ThrombVasc Biol 2001; 21: 1393-401.
50. Thompson RW, Curci JA, Ennis TL, Mao D, Pagano MB, PhamCT. Pathophysiology of abdominal aortic aneurysms: insights fromthe elastase-induced model in mice with different genetic backgrounds. Ann N Y Acad Sci 2006; 1085: 59-73.
51. Holmes DR, Petrinec D, Wester W, Thompson RW, Reilly JM. Indomethacin prevents elastase-induced abdominal aortic aneurysmsin the rat. J Surg Res 1996; 63: 305-9.
52. Kalyanasundaram A, Elmore JR, Manazer JR, et al. Simvastatinsuppresses experimental aortic aneurysm expansion. J Vasc Surg2006; 43: 117-24.
53. Shiraya S, Miyake T, Aoki M, et al. Inhibition of development ofexperimental aortic abdominal aneurysm in rat model by atorvastatinthrough inhibition of macrophage migration. Atherosclerosis2009; 202: 34-40.
54. Ricci MA, Slaiby JM, Gadowski GR, Hendley ED, Nichols P, Pilcher DB. Effects of hypertension and propranolol upon aneurysmexpansion in the Anidjar/Dobrin aneurysm model. Ann N YAcad Sci 1996; 800: 89-96.
55. Tomita N, Yamasaki K, Izawa K, et al. Inhibition of experimentalabdominal aortic aneurysm progression by nifedipine. Int J MolMed 2008; 21: 239-44.
56. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, ThompsonRW. Suppression of experimental abdominal aortic aneurysms inthe rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001; 33: 1057-64.
57. Fujiwara Y, Shiraya S, Miyake T, et al. Inhibition of experimentalabdominal aortic aneurysm in a rat model by the angiotensin receptorblocker valsartan. Int J Mol Med 2008; 22: 703-8.
58. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologicsuppression of experimental abdominal aortic aneurysms:acomparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998; 28: 1082-93.
59. Nakashima H, Aoki M, Miyake T, et al. Inhibition of experimentalabdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotidessuppressing activity of nuclear factor kappaB andets transcription factors. Circulation 2004; 109: 132-8.
60. Miyake T, Aoki M, Nakashima H, et al. Prevention of abdominalaortic aneurysms by simultaneous inhibition of NFkappaB and etsusing chimeric decoy oligonucleotides in a rabbit model. GeneTher 2006; 13: 695-704.
61. Miyama N, Sato A, Matsubara M, Watanabe T, Ikada Y, Satomi S. Inhibitory effects of a biodegradable gelatin hydrogel sponge sheeton the progression of experimental abdominal aortic aneurysms. Ann Vasc Surg 2009; 23: 224-30.
62. Carsten CG, III, Calton WC, Johanning JM, et al. Elastase is notsufficient to induce experimental abdominal aortic aneurysms. JVasc Surg 2001; 33: 1255-62.
63. Tanaka A, Hasegawa T, Chen Z, Okita Y, Okada K. A novel ratmodel of abdominal aortic aneurysm using a combination of intraluminalelastase infusion and extraluminal calcium chloride exposure. J Vasc Surg 2009; 50: 1423-32.
64. Reinald N, Fournier B, Naveau A, et al. Fusiform aneurysm modelin rabbit carotid artery. J Vasc Res 2010; 47: 61-8.
65. Strindberg G, Nichols P, Ricci MA, et al. Experimental modificationsto a canine infrarenal aortic aneurysm model for the validationof endovascular stent-grafts: an exploratory study. J InvestSurg 1998; 11: 185-97.
66. Marinov GR, Marois Y, Paris E, et al. Can the infusion of elastasein the abdominal aorta of the Yucatan miniature swine consistentlyproduce experimental aneurysms? J Invest Surg 1997; 10: 129-50.
67. Hynecek RL, DeRubertis BG, Trocciola SM, et al. The creation ofan infrarenal aneurysm within the native abdominal aorta of swine. Surgery 2007; 142: 143-9.
68. Manning MW, Cassi LA, Huang J, Szilvassy SJ, Daugherty A. Abdominal aortic aneurysms: fresh insights from a novel animalmodel of the disease. Vasc Med 2002; 7: 45-54.
69. Rush C, Nyara M, Moxon JV, Trollope A, Cullen B, Golledge J. Whole genome expression analysis within the angiotensin IIapolipoproteinE deficient mouse model of abdominal aortic aneurysm. BMC Genomics 2009; 10: 298.
70. Daugherty A, Rateri DL, Cassis LA. Role of the renin-angiotensinsystem in the development of abdominal aortic aneurysms inanimals and humans. Ann N Y Acad Sci 2006; 1085: 82-91.
71. Cassis LA, Gupte M, Thayer S, et al. ANG II infusion promotesabdominal aortic aneurysms independent of increased bloodpressure in hypercholesterolemic mice. Am J Physiol Heart CircPhysiol 2009; 296: H1660-65.
72. Martin-McNulty B, Tham DM, da Cunha V, et al. 17 Beta-estradiolattenuates development of angiotensin II-induced aortic abdominalaneurysm in apolipoprotein E-deficient mice. Arterioscler ThrombVasc Biol 2003; 23: 1627-32.
73. Henriques T, Zhang X, Yiannikouris FB, Daugherty A, Cassis LA. Androgen increases AT1a receptor expression in abdominal aortasto promote angiotensin II-induced AAAs in apolipoprotein Edeficientmice. Arterioscler Thromb Vasc Biol 2008; 28: 1251-6.
74. Henriques TA, Huang J, D'Souza SS, Daugherty A, Cassis LA. Orchidectomy, but not ovariectomy, regulates angiotensin IIinducedvascular diseases in apolipoprotein E-deficient mice. Endocrinology 2004; 145: 3866-72.
75. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2receptors augments angiotensin II-induced abdominal aorticaneurysms and atherosclerosis. Br J Pharmacol 2001; 134: 865-70.
76. Inoue N, Muramatsu M, Jin D, et al. Involvement of vascular angiotensinII-forming enzymes in the progression of aortic abdominalaneurysms in angiotensin II-infused ApoE-deficient mice. JAtheroscler Thromb 2009; 16: 164-71.
77. Cassis LA, Helton MJ, Howatt DA, King VL, Daugherty A. Aldosteronedoes not mediate angiotensin II-induced atherosclerosis andabdominal aortic aneurysms. Br J Pharmacol 2005; 144: 443-8.
78. Manning MW, Cassis LA, Daugherty A. Differential effects ofdoxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aorticaneurysms. Arterioscler Thromb Vasc Biol 2003; 23: 483-8.
79. Gavrila D, Li WG, McCormick ML, et al. Vitamin E inhibitsabdominal aortic aneurysm formation in angiotensin II-infusedapolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol2005; 25: 1671-7.
80. Zhang Y, Naggar JC, Welzig CM, et al. Simvastatin inhibits angiotensinII-induced abdominal aortic aneurysm formation in apolipoproteinE-knockout mice: possible role of ERK. ArteriosclerThromb Vasc Biol 2009; 29: 1764-71.
81. Jones A, Deb R, Torsney E, et al. Rosiglitazone reduces the developmentand rupture of experimental aortic aneurysms. Circulation2009; 119: 3125-32.
82. Deng GG, Martin-McNulty B, Sukovich DA, et al. Urokinase-typeplasminogen activator plays a critical role in angiotensin II-inducedabdominal aortic aneurysm. Circ Res 2003; 92: 510-17.
83. Qian HS, Gu JM, Liu P, et al. Overexpression of PAI-1 preventsthe development of abdominal aortic aneurysm in mice. Gene Ther2008; 15: 224-32.
84. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD. Genetic deficiencyof cyclooxygenase-2 attenuates abdominal aortic aneurysmformation in mice. Cardiovasc Res 2007; 73: 227-36.
85. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graftimplantation for abdominal aortic aneurysms. Ann Vasc Surg 1991;5: 491-9.
86. Economou SG, Taylor CB, Beattie EJ, Jr., Davis CB, Jr. Persistentexperimental aortic aneurysms in dogs. Surgery 1960; 47: 21-8.
87. Ammirati M, Ostertag H, Rabin E, Ciric I. Pathology of laserinducedexperimental aneurysms. Lasers Surg Med 1988; 8: 308-17.
88. Quigley MR, Heiferman K, Kwaan HC, Vidovich D, Nora P, Cerullo LJ. Laser-sealed arteriotomy: a reliable aneurysm model. JNeurosurg 1987; 67: 284-7.
89. White JC, Sayre GP, Whisnant JP. Experimental destruction ofthe media for the production of intracranial arterial aneurysms. JNeurosurg 1961; 18: 741-5.
90. Laborde JC, Parodi JC, Clem MF, et al. Intraluminal bypass ofabdominal aortic aneurysm: feasibility study. Radiology 1992; 184:185-90.
91. Whitbread T, Birch P, Rogers S, et al. A new animal model forabdominal aortic aneurysms: initial results using a multiple-wirestent. Eur J Vasc Endovasc Surg 1996; 11: 90-7.
92. Criado E, Marston WA, Woosley JT, et al. An aortic aneurysmmodel for the evaluation of endovascular exclusion prostheses. JVasc Surg 1995; 22: 306-14.
93. Eton D, Warner D, Owens C, et al. Results of endoluminal graftingin an experimental aortic aneurysm model. J Vasc Surg 1996; 23:819-29.
94. Becquemin JP, Kelley L, Zubilewicz T, Desgranges P, Lapeyre M, Kobeiter H. Outcomes of secondary interventions after abdominalaortic aneurysm endovascular repair. J Vasc Surg 2004; 39: 298-305.
95. Brewster DC, Jones JE, Chung TK, et al. Long-term outcomes afterendovascular abdominal aortic aneurysm repair: the first decade. Ann Surg 2006; 244: 426-38.
96. Schlosser FJ, Gusberg RJ, Dardik A, et al. Aneurysm rupture afterEVAR: can the ultimate failure be predicted? Eur J Vasc EndovascSurg 2009; 37: 15-22.
97. Mousa A, Dayal R, Bernheim J, et al. A canine model to study thesignificance and hemodynamics of type II endoleaks. J Surg Res2005; 123: 275-83.
98. Diaz S, Uzieblo MR, Desai KM, et al. Type II endoleak in porcinemodel of abdominal aortic aneurysm. J Vasc Surg 2004; 40: 339-44.
99. Maynar M, Qian Z, Hernandez J, et al. An animal model ofabdominal aortic aneurysm created with peritoneal patch: techniqueand initial results. Cardiovasc Intervent Radiol 2003; 26: 168-76.
100. Sadek M, Hynecek RL, Goldenberg S, Kent KC, Marin ML, FariesPL. Gene expression analysis of a porcine native abdominal aorticaneurysm model. Surgery 2008; 144: 252-8.
101. Molacek J, Treska V, Kobr J, Certik B, Skalicky T, KuntscherV, Krizkova V. Optimization of the model of abdominal aorticaneurysm-experiment in an animal model. J Vasc Res 2009; 45:1-5.
102. Kostering H, Mast WP, Kaethner T, Nebendahl K, Holtz WH. Blood coagulation studies in domestic pigs (Hanover breed) andminipigs (Goettingen breed). Lab Anim 1983; 17: 346-9.